Evidence map›Paper›PMID 40533862›Full record

ArticleCell & bioscience2025

Generation of a spontaneous murine HPV + oral cancer model with site-specific oncogene insertion using CRISPR-SONIC.

Julia Tao, Jason Murray, Hsin-Fang Tu, Darrell Fan, Ya-Chea Tsai, Ming-Hung Hu, Annie A Wu, Deyin Xing, Chien-Fu Hung, T-C Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell & bioscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Julia TaoDepartment of Pathology, Johns Hopkins University School of Medicine, 1550 Orleans Street, CRB II 307, Baltimore, MD, 21287, USA.
Jason MurrayDepartment of Pathology, Johns Hopkins University School of Medicine, 1550 Orleans Street, CRB II 307, Baltimore, MD, 21287, USA.
Hsin-Fang TuDepartment of Pathology, Johns Hopkins University School of Medicine, 1550 Orleans Street, CRB II 307, Baltimore, MD, 21287, USA.
Darrell FanDepartment of Pathology, Johns Hopkins University School of Medicine, 1550 Orleans Street, CRB II 307, Baltimore, MD, 21287, USA.
Ya-Chea TsaiDepartment of Pathology, Johns Hopkins University School of Medicine, 1550 Orleans Street, CRB II 307, Baltimore, MD, 21287, USA.
Ming-Hung HuDepartment of Pathology, Johns Hopkins University School of Medicine, 1550 Orleans Street, CRB II 307, Baltimore, MD, 21287, USA.
Annie A WuDepartment of Pathology, Johns Hopkins University School of Medicine, 1550 Orleans Street, CRB II 307, Baltimore, MD, 21287, USA.
Deyin XingDepartment of Pathology, Johns Hopkins University School of Medicine, 1550 Orleans Street, CRB II 307, Baltimore, MD, 21287, USA.
Chien-Fu HungDepartment of Pathology, Johns Hopkins University School of Medicine, 1550 Orleans Street, CRB II 307, Baltimore, MD, 21287, USA. chung2@jhmi.edu.
T-C WuDepartment of Pathology, Johns Hopkins University School of Medicine, 1550 Orleans Street, CRB II 307, Baltimore, MD, 21287, USA. wutc@jhmi.edu.ORCID http://orcid.org/0000-0003-1623-4584

Funding

Treatment of HIV- and HIV+ Patients with HPV16+ CIN2/3 Using pNGLV4a-hCRTE6E7L2 DNA vaccine administered intramuscularly via electroporationP50CA098252 · NCI · JOHNS HOPKINS UNIVERSITY · PI WARNER KING HUH, TZYY-CHOOU WU · 2003 to 2026
$53.5M
Development of Novel Spontaneous HPV Cervicovaginal Carcinoma Models for Cancer ImmunotherapyR01CA237067 · NCI · JOHNS HOPKINS UNIVERSITY · PI WU, TZYY-CHOOU · 2019 to 2023
$2.9M
Strategies to Reduce Global Health Disparities in Cervical CancerR01CA295696 · NCI · JOHNS HOPKINS UNIVERSITY · PI TZYY-CHOOU WU · 2025 to 2026
$1.3M
Novel immunotherapeutic regimen combining the dendritic cell expansion power of Albumin-Flt3L and inflammatory cues of SalmonellaR21DE029910 · NIDCR · JOHNS HOPKINS UNIVERSITY · PI HUNG, CHIEN-FU · 2020 to 2021
$450k
Albumin-FMS-like tyrosine kinase 3 ligand (Alb-Flt3L) fusion protein as a novel adjuvant to enhance the immunogenicity and therapeutic and prophylactic efficacies of a HPV protein vaccineR21CA234516 · NCI · JOHNS HOPKINS UNIVERSITY · PI HUNG, CHIEN-FU · 2020 to 2021
$421k
Novel strategy combined with targeted radiation therapy unleashes potentantitumor immunity in HPV + head and neck cancerR21CA256020 · NCI · JOHNS HOPKINS UNIVERSITY · PI HUNG, CHIEN-FU · 2021 to 2022
$417k
NCI NIH HHS 1R21CA234516-01A1NCI NIH HHS P50 CA098252NCI NIH HHS P50CA098252NCI NIH HHS R01 CA237067NCI NIH HHS R01CA237067NCI NIH HHS R01 CA295696NCI NIH HHS R21 CA234516NCI NIH HHS R21 CA256020NCI NIH HHS R21CA256020NCI NIH HHS R21DE029910-01NIDCR NIH HHS R21 DE029910
6 · The paper itself

Abstract

Human papillomavirus associated head and neck cancer (HPV + HNC) is rising globally, emphasizing the need for improved therapeutic and screening strategies. To test novel therapies and study HPV-related disease progression, it is vital to develop relevant preclinical models. However, many fail to address critical concerns, including generating a representative immune microenvironment and adequately modeling HPV-driven malignant transformation. Recent multi-omics studies reveal the significance of HPV integration location in HPV-related carcinogenesis and highlight the necessity of targeted treatment methods. Thus, we have developed a murine model of HPV16 + HNC modifying the published CRISPR-based Somatic Oncogene kNock-In for Cancer Modeling (CRISPR-SONIC) system for precise integration of HPV oncogenes. We showed that CRISPR-SONIC knock-in of Kras

Indexed as

Buccal tumorCRISPR-SONICE6E7Head and neck cancerHPV16Human papillomavirusImmunotherapyMurine modelRas

Identifiers

PMID40533862
PMCPMC12175459

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.